Risum Malene, Hare Rasmus Krøger, Gertsen Jan Berg, Kristensen Lise, Johansen Helle Krogh, Helweg-Larsen Jannik, Abou-Chakra Nissrine, Pressler Tacjana, Skov Marianne, Jensen-Fangel Søren, Arendrup Maiken Cavling
Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark.
Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark.
Front Microbiol. 2020 Aug 13;11:1850. doi: 10.3389/fmicb.2020.01850. eCollection 2020.
Azole-resistant (azole-R) is an increasing challenge worldwide. Patients with cystic fibrosis (CF) are at risk of colonization and disease due to a favorable lung environment for microorganisms. We performed a nationwide study in 2018 of azole-non-susceptible in CF patients and compared with data from two prior studies. All airway samples with mold isolates from patients monitored at the two CF centers in Denmark (RH, Jan-Sept and AUH, Jan-Jun) were included. Classical species identification (morphology and thermo-tolerance) was performed and MALDI-TOF/β-tubulin sequencing was performed if needed. Susceptibility was determined using EUCAST E.Def 10.1, and E.Def 9.3.2. sequencing and STR genotyping were performed for azole-non-susceptible isolates and relevant sequential isolates. In total, 340 mold isolates from 159 CF patients were obtained. The most frequent species were (266/340, 78.2%) and (26/340, 7.6%). Azole-R was cultured from 7.3% (10/137) of patients, including 9.5% (9/95) of patients at RH and 2.4% at AUH (1/42), respectively. In a 10-year perspective, azole-non-susceptibility increased numerically among patients at RH (10.5% in 2018 vs 4.5% in 2007-2009). Cyp51A resistance mechanisms were found in nine azole-R from eight CF patients. Five were of environmental origin (TR/L98H), three were human medicine-driven (two M220K and one M220R), and one was novel (TR /L98H) and found in a patient who also harbored a TR/L98H isolate. STR genotyping identified 27 unique genotypes among 45 isolates and ≥2 genotypes in 8 of 12 patients. This included one patient carrying two unique TR/L98H isolates, a rare phenomenon. Genotyping of sequential TR /L98H and TR/L98H isolates from the same patient showed only minor differences in 1/9 markers. Finally, azole-R was found in three patients including two with Cyp51A alterations (M217I and G51A, respectively). Azole-R is increasing among CF patients in Denmark with the environmentally associated resistance TR/L98H mechanism being dominant. Mixed infections (wildtype/non-wildtype and several non-wildtypes) and a case of potential additional tandem repeat acquisition were found. However, similar genotypes were identified from another patient (and outside this study), potentially suggesting a predominant TR/L98H clone in DK. These findings suggest an increasing prevalence and complexity of azole resistance in .
唑类耐药(azole-R)在全球范围内构成的挑战日益严峻。囊性纤维化(CF)患者由于肺部环境利于微生物生存,因而面临着定植和患病的风险。我们在2018年针对CF患者中对唑类不敏感的情况开展了一项全国性研究,并与此前两项研究的数据进行了比较。纳入了丹麦两个CF中心(RH,1月至9月;AUH,1月至6月)监测的所有从患者气道样本中分离出的霉菌。进行了经典的菌种鉴定(形态学和耐热性),必要时进行基质辅助激光解吸电离飞行时间质谱/β-微管蛋白测序。使用欧盟CAST E.Def 10.1和E.Def 9.3.2确定药敏性。对唑类不敏感菌株及相关连续分离株进行测序和STR基因分型。总共从159例CF患者中获得了340株霉菌分离株。最常见的菌种是(266/340,78.2%)和(26/340,7.6%)。7.3%(10/137)的患者培养出唑类耐药菌株,其中RH的患者中9.5%(9/95)培养出该菌株,AUH的患者中2.4%(1/42)培养出该菌株。从10年的时间跨度来看,RH的患者中对唑类不敏感的比例在数值上有所增加(2018年为10.5%,而2007 - 2009年为4.5%)。在8例CF患者的9株唑类耐药菌株中发现了Cyp51A耐药机制。其中5株源于环境(TR/L98H),3株是由人类用药导致的(2株M220K和1株M220R),还有1株是新发现的(TR /L98H),在一名同时携带TR/L98H分离株的患者中发现。STR基因分型在45株分离株中鉴定出27种独特基因型,12例患者中有8例存在≥2种基因型。这包括一名携带两种独特TR/L98H分离株的患者,这是一种罕见现象。对同一患者连续的TR /L98H和TR/L98H分离株进行基因分型显示,在1/9个标记中只有微小差异。最后,在3例患者中发现了唑类耐药菌株,其中2例分别存在Cyp51A改变(M217I和G51A)。丹麦CF患者中唑类耐药情况呈上升趋势,与环境相关的TR/L98H耐药机制占主导。发现了混合感染(野生型/非野生型以及几种非野生型)以及一例可能额外获得串联重复序列的病例。然而,在另一名患者中(以及本研究之外)鉴定出了相似的基因型,这可能表明丹麦存在占主导地位的TR/L98H克隆。这些发现表明CF中唑类耐药的患病率和复杂性在增加。